Dyne Therapeutics, Inc.
DYN
$9.57
-$0.48-4.78%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -35.31% | 73.03% | 83.12% | 27.52% | 210.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 76.95% | 43.46% | 69.67% | 7.83% | 52.11% |
| Operating Income | -76.95% | -43.46% | -69.67% | -7.83% | -52.11% |
| Income Before Tax | -75.72% | -34.37% | -61.31% | -0.31% | -48.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -75.72% | -34.37% | -61.31% | -0.31% | -48.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -75.72% | -34.37% | -61.31% | -0.31% | -48.57% |
| EBIT | -76.95% | -43.46% | -69.67% | -7.83% | -52.11% |
| EBITDA | -77.21% | -43.65% | -70.14% | -7.93% | -52.65% |
| EPS Basic | -29.58% | 19.11% | 2.28% | 35.12% | -3.25% |
| Normalized Basic EPS | -29.57% | 19.10% | 2.29% | 35.12% | -3.26% |
| EPS Diluted | -29.58% | 19.11% | 2.28% | 35.12% | -3.25% |
| Normalized Diluted EPS | -29.57% | 19.10% | 2.29% | 35.12% | -3.26% |
| Average Basic Shares Outstanding | 35.62% | 66.11% | 65.08% | 54.60% | 43.88% |
| Average Diluted Shares Outstanding | 35.62% | 66.11% | 65.08% | 54.60% | 43.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |